Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Implementation of a decision aid for localized prostate cancer in routine care: A successful implementation strategy.

van Tol-Geerdink JJ, van Oort IM, Somford DM, Wijburg CJ, Geboers A, van Uden-Kraan CF, de Vries M, Stalmeier PF.

Health Informatics J. 2019 Sep 30:1460458219873528. doi: 10.1177/1460458219873528. [Epub ahead of print]

PMID:
31566466
2.

Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative.

Cuypers M, Al-Itejawi HHM, van Uden-Kraan CF, Stalmeier PFM, Lamers RED, van Oort IM, Somford DM, van Moorselaar RJA, Verdonck-de Leeuw IM, van de Poll-Franse LV, van Tol-Geerdink JJ, de Vries M.

J Cancer Educ. 2019 Jul 5. doi: 10.1007/s13187-019-01572-9. [Epub ahead of print]

PMID:
31278659
3.

Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus.

Hajdu K, Brodszky V, Stalmeier PFM, Ruzsa G, Tamási B, Gulácsi L, Péntek M, Sárdy M, Bata-Csörgő Z, Kinyó Á, Szegedi A, Rencz F.

J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2106-2113. doi: 10.1111/jdv.15765. Epub 2019 Jul 26.

PMID:
31265151
4.

Cultural Values: Can They Explain Differences in Health Utilities between Countries?

Roudijk B, Donders ART, Stalmeier PFM; Cultural Values Group.

Med Decis Making. 2019 Jul;39(5):605-616. doi: 10.1177/0272989X19841587. Epub 2019 Jul 1.

5.

Patient and general population values for luminal and perianal fistulising Crohn's disease health states.

Rencz F, Stalmeier PFM, Péntek M, Brodszky V, Ruzsa G, Gönczi L, Palatka K, Herszényi L, Schäfer E, Banai J, Rutka M, Gulácsi L, Lakatos PL.

Eur J Health Econ. 2019 Jun;20(Suppl 1):91-100. doi: 10.1007/s10198-019-01065-y. Epub 2019 May 17.

6.

Quality-Adjusted Life-Years without Constant Proportionality.

Craig BM, Rand K, Bailey H, Stalmeier PFM.

Value Health. 2018 Sep;21(9):1124-1131. doi: 10.1016/j.jval.2018.02.004. Epub 2018 Mar 27.

7.

Shared decision-making for postoperative analgesia: A semistructured qualitative study.

van den Berg AMA, Stalmeier PFM, Scheffer GJ, Hermens RP, Bucx MJL.

Eur J Anaesthesiol. 2019 Jan;36(1):25-31. doi: 10.1097/EJA.0000000000000864.

PMID:
30063536
8.

Setting Dead at Zero: Applying Scale Properties to the QALY Model.

Roudijk B, Donders ART, Stalmeier PFM.

Med Decis Making. 2018 Aug;38(6):627-634. doi: 10.1177/0272989X18765184. Epub 2018 Apr 9. Review.

9.

Explanation and elaboration of the Standards for UNiversal reporting of patient Decision Aid Evaluations (SUNDAE) guidelines: examples of reporting SUNDAE items from patient decision aid evaluation literature.

Hoffman AS, Sepucha KR, Abhyankar P, Sheridan S, Bekker H, LeBlanc A, Levin C, Ropka M, Shaffer V, Stacey D, Stalmeier P, Vo H, Wills C, Thomson R.

BMJ Qual Saf. 2018 May;27(5):389-412. doi: 10.1136/bmjqs-2017-006985. Epub 2018 Feb 21.

10.

Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist.

Sepucha KR, Abhyankar P, Hoffman AS, Bekker HL, LeBlanc A, Levin CA, Ropka M, Shaffer VA, Sheridan SL, Stacey D, Stalmeier P, Vo H, Wills CE, Thomson R.

BMJ Qual Saf. 2018 May;27(5):380-388. doi: 10.1136/bmjqs-2017-006986. Epub 2017 Dec 21.

11.

Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial.

Oostendorp LJM, Ottevanger PB, Donders ART, van de Wouw AJ, Schoenaker IJH, Smilde TJ, van der Graaf WTA, Stalmeier PFM.

BMC Med Inform Decis Mak. 2017 Aug 31;17(1):130. doi: 10.1186/s12911-017-0529-y.

12.

Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods.

Rencz F, Péntek M, Stalmeier PFM, Brodszky V, Ruzsa G, Gradvohl E, Baji P, Gulácsi L.

Pain. 2017 Nov;158(11):2259-2267. doi: 10.1097/j.pain.0000000000001028.

PMID:
28767507
13.

Shared decision making, a buzz-word in the Netherlands, the pace quickens towards nationwide implementation….

van der Weijden T, Post H, Brand PLP, van Veenendaal H, Drenthen T, van Mierlo LA, Stalmeier P, Damman OC, Stiggelbout A.

Z Evid Fortbild Qual Gesundhwes. 2017 Jun;123-124:69-74. doi: 10.1016/j.zefq.2017.05.016. Epub 2017 May 19. Review.

PMID:
28529122
14.

The use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review.

Wichmann AB, Adang EM, Stalmeier PF, Kristanti S, Van den Block L, Vernooij-Dassen MJ, Engels Y; PACE.

Palliat Med. 2017 Apr;31(4):306-322. doi: 10.1177/0269216316689652. Epub 2017 Feb 13. Review.

15.

Cultural values: can they explain self-reported health?

Roudijk B, Donders R, Stalmeier P.

Qual Life Res. 2017 Jun;26(6):1531-1539. doi: 10.1007/s11136-017-1512-x. Epub 2017 Feb 10.

16.

Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment.

Rencz F, Brodszky V, Stalmeier PF, Tamási B, Kárpáti S, Péntek M, Baji P, Mitev AZ, Gulácsi L.

Br J Dermatol. 2016 Sep;175(3):593-9. doi: 10.1111/bjd.14647. Epub 2016 Aug 8.

PMID:
27062497
17.

Synkinesis assessment in facial palsy: validation of the Dutch Synkinesis Assessment Questionnaire.

Kleiss IJ, Beurskens CH, Stalmeier PF, Ingels KJ, Marres HA.

Acta Neurol Belg. 2016 Jun;116(2):171-8. doi: 10.1007/s13760-015-0528-7. Epub 2015 Sep 16.

18.

Patients' Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist's Awareness of These Preferences.

Oostendorp LJ, Ottevanger PB, van de Wouw AJ, Honkoop AH, Los M, van der Graaf WT, Stalmeier PF.

J Cancer Educ. 2016 Sep;31(3):443-8. doi: 10.1007/s13187-015-0845-9.

19.

Does a decision aid for prostate cancer affect different aspects of decisional regret, assessed with new regret scales? A randomized, controlled trial.

van Tol-Geerdink JJ, Leer JW, Wijburg CJ, van Oort IM, Vergunst H, van Lin EJ, Witjes JA, Stalmeier PF.

Health Expect. 2016 Apr;19(2):459-70. doi: 10.1111/hex.12369. Epub 2015 May 3.

20.

Quality of life assessment in facial palsy: validation of the Dutch Facial Clinimetric Evaluation Scale.

Kleiss IJ, Beurskens CH, Stalmeier PF, Ingels KJ, Marres HA.

Eur Arch Otorhinolaryngol. 2015 Aug;272(8):2055-61. doi: 10.1007/s00405-015-3508-x. Epub 2015 Jan 28.

21.

Expected survival with and without second-line palliative chemotherapy: who wants to know?

Oostendorp LJ, Ottevanger PB, van de Wouw AJ, Schoenaker IJ, de Graaf H, van der Graaf WT, Stalmeier PF.

Health Expect. 2015 Dec;18(6):2903-14. doi: 10.1111/hex.12275. Epub 2014 Oct 10.

22.

Values for health states with different life durations.

Scalone L, Stalmeier PF, Milani S, Krabbe PF.

Eur J Health Econ. 2015 Dec;16(9):917-25. doi: 10.1007/s10198-014-0634-0. Epub 2014 Sep 30.

PMID:
25266301
23.

Exploring the Routine Administration of Decision Aids for Palliative Chemotherapy to Patients by Nurses: A Qualitative Study Among Nurses and Oncologists.

Oostendorp LJ, Ottevanger PB, van der Graaf WT, Peters ME, Hermens RP, Stalmeier PF.

Cancer Nurs. 2015 Jul-Aug;38(4):270-8. doi: 10.1097/NCC.0000000000000182.

PMID:
25101927
24.

The better than dead method: feasibility and interpretation of a valuation study.

van Hoorn RA, Donders AR, Oppe M, Stalmeier PF.

Pharmacoeconomics. 2014 Aug;32(8):789-99. doi: 10.1007/s40273-014-0168-4.

PMID:
24846761
25.

Quality of life after prostate cancer treatments in patients comparable at baseline.

van Tol-Geerdink JJ, Leer JW, van Oort IM, van Lin EJ, Weijerman PC, Vergunst H, Witjes JA, Stalmeier PF.

Br J Cancer. 2013 May 14;108(9):1784-9. doi: 10.1038/bjc.2013.181. Epub 2013 Apr 23.

26.

Balancing the presentation of information and options in patient decision aids: an updated review.

Abhyankar P, Volk RJ, Blumenthal-Barby J, Bravo P, Buchholz A, Ozanne E, Vidal DC, Col N, Stalmeier P.

BMC Med Inform Decis Mak. 2013;13 Suppl 2:S6. doi: 10.1186/1472-6947-13-S2-S6. Epub 2013 Nov 29. Review.

27.

TIPP and Lichtenstein modalities for inguinal hernia repair: a cost minimisation analysis alongside a randomised trial.

Koning GG, Adang EM, Stalmeier PF, Keus F, Vriens PW, van Laarhoven CJ.

Eur J Health Econ. 2013 Dec;14(6):1027-34. doi: 10.1007/s10198-012-0453-0. Epub 2012 Dec 28.

PMID:
23271350
28.

Maximal endurable time states and the standard gamble: more preference reversals.

Stalmeier PF, Verheijen AL.

Eur J Health Econ. 2013 Dec;14(6):971-7. doi: 10.1007/s10198-012-0445-0. Epub 2012 Dec 9.

PMID:
23224226
29.

Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.

van Tol-Geerdink JJ, Willem Leer J, Weijerman PC, van Oort IM, Vergunst H, van Lin EN, Alfred Witjes J, Stalmeier PF.

BJU Int. 2013 Apr;111(4):564-73. doi: 10.1111/j.1464-410X.2012.11402.x. Epub 2012 Aug 10.

30.

[Adjuvant cancer treatment: what benefit does the patient consider worthwhile?].

Pieterse AH, Stalmeier PF, Kroep JR, Stiggelbout AM.

Ned Tijdschr Geneeskd. 2011;155(45):A3905. Review. Dutch.

PMID:
22085571
31.

A measure of control.

Stalmeier PF, Hamm RM.

Med Decis Making. 2011 Sep-Oct;31(5):705-6. doi: 10.1177/0272989X11418673. No abstract available.

PMID:
21921148
32.

Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.

Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT, Ottevanger PB.

Lancet Oncol. 2011 Oct;12(11):1053-61. doi: 10.1016/S1470-2045(11)70045-6. Epub 2011 May 27. Review.

PMID:
21621462
33.

Shared decision making in the Netherlands, is the time ripe for nationwide, structural implementation?

van der Weijden T, van Veenendaal H, Drenthen T, Versluijs M, Stalmeier P, Koelewijn-van Loon M, Stiggelbout A, Timmermans D.

Z Evid Fortbild Qual Gesundhwes. 2011;105(4):283-8. doi: 10.1016/j.zefq.2011.04.005. Epub 2011 Apr 30.

PMID:
21620322
34.

Assessing the information desire of patients with advanced cancer by providing information with a decision aid, which is evaluated in a randomized trial: a study protocol.

Oostendorp LJ, Ottevanger PB, van der Graaf WT, Stalmeier PF.

BMC Med Inform Decis Mak. 2011 Feb 14;11:9. doi: 10.1186/1472-6947-11-9.

35.

Depression related to (neo)adjuvant hormonal therapy for prostate cancer.

van Tol-Geerdink JJ, Leer JW, van Lin EN, Schimmel EC, Stalmeier PF.

Radiother Oncol. 2011 Feb;98(2):203-6. doi: 10.1016/j.radonc.2010.12.006. Epub 2011 Jan 20.

PMID:
21256610
36.

The effect of a multifaceted empowerment strategy on decision making about the number of embryos transferred in in vitro fertilisation: randomised controlled trial.

van Peperstraten A, Nelen W, Grol R, Zielhuis G, Adang E, Stalmeier P, Hermens R, Kremer J.

BMJ. 2010 Sep 30;341:c2501. doi: 10.1136/bmj.c2501.

37.

Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.

Oostendorp LJ, Stalmeier PF, Pasker-de Jong PC, Van der Graaf WT, Ottevanger PB.

Anticancer Drugs. 2010 Sep;21(8):749-58. doi: 10.1097/CAD.0b013e32833c57cf. Review.

PMID:
20616701
38.

Adherence and decision AIDS: a model and a narrative review.

Stalmeier PF.

Med Decis Making. 2011 Jan-Feb;31(1):121-9. doi: 10.1177/0272989X10370487. Epub 2010 Jun 2. Review.

PMID:
20519453
39.

The relationship between change in subjective outcome and change in disease: a potential paradox.

Kievit W, Hendrikx J, Stalmeier PF, van de Laar MA, Van Riel PL, Adang EM.

Qual Life Res. 2010 Sep;19(7):985-94. doi: 10.1007/s11136-010-9665-x. Epub 2010 May 8.

40.

Deciding how many embryos to transfer after in vitro fertilisation: development and pilot test of a decision aid.

van Peperstraten AM, Hermens RP, Nelen WL, Stalmeier PF, Wetzels AM, Maas PH, Kremer JA, Grol RP.

Patient Educ Couns. 2010 Jan;78(1):124-9. doi: 10.1016/j.pec.2009.04.007. Epub 2009 May 21.

PMID:
19464139
41.

[The patient chooses for feasibility and effectiveness].

Stalmeier PF, van Tol-Geerdink JJ, van Lin EN, Schimmel E, Huizenga H, van Daal WA, Leer JW.

Ned Tijdschr Geneeskd. 2009 Mar 28;153(13):600-6. Dutch. No abstract available.

PMID:
19408536
42.

Perceived barriers to elective single embryo transfer among IVF professionals: a national survey.

van Peperstraten AM, Hermens RP, Nelen WL, Stalmeier PF, Scheffer GJ, Grol RP, Kremer JA.

Hum Reprod. 2008 Dec;23(12):2718-23. doi: 10.1093/humrep/den327. Epub 2008 Sep 4.

PMID:
18775886
43.

Concise evaluation of decision aids.

Stalmeier PF, Roosmalen MS.

Patient Educ Couns. 2009 Jan;74(1):104-9. doi: 10.1016/j.pec.2008.07.043. Epub 2008 Sep 4.

PMID:
18775622
44.

Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret.

van Dijk S, van Roosmalen MS, Otten W, Stalmeier PF.

J Clin Oncol. 2008 May 10;26(14):2358-63. doi: 10.1200/JCO.2006.10.5494.

PMID:
18467728
45.

Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being.

van Tol-Geerdink JJ, Leer JW, van Lin EN, Schimmel EC, Huizenga H, van Daal WA, Stalmeier PF.

Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):442-8. Epub 2007 Aug 31.

PMID:
17765404
46.

On the assessment of preferences for health and duration: maximal endurable time and better than dead preferences.

Stalmeier PF, Lamers LM, Busschbach JJ, Krabbe PF.

Med Care. 2007 Sep;45(9):835-41.

PMID:
17712253
47.

Doctors' and patients' preferences for participation and treatment in curative prostate cancer radiotherapy.

Stalmeier PF, van Tol-Geerdink JJ, van Lin EN, Schimmel E, Huizenga H, van Daal WA, Leer JW.

J Clin Oncol. 2007 Jul 20;25(21):3096-100.

PMID:
17634489
48.

Prospective patient and physician preferences for stimulation or no stimulation in IVF.

Pistorius EN, Adang EM, Stalmeier PF, Braat DD, Kremer JA.

Hum Fertil (Camb). 2006 Dec;9(4):209-16.

PMID:
17190666
49.

Testing the interval-level measurement property of multi-item visual analogue scales.

Krabbe PF, Stalmeier PF, Lamers LM, Busschbach JJ.

Qual Life Res. 2006 Dec;15(10):1651-61. Epub 2006 Sep 20.

PMID:
17031501
50.

Do patients with localized prostate cancer treatment really want more aggressive treatment?

van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, Schimmel EC, Huizenga H, van Daal WA, Leer JW.

J Clin Oncol. 2006 Oct 1;24(28):4581-6.

PMID:
17008699

Supplemental Content

Loading ...
Support Center